These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7636988)

  • 1. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.
    Maschera B; Furfine E; Blair ED
    J Virol; 1995 Sep; 69(9):5431-6. PubMed ID: 7636988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.
    Partaledis JA; Yamaguchi K; Tisdale M; Blair EE; Falcione C; Maschera B; Myers RE; Pazhanisamy S; Futer O; Cullinan AB
    J Virol; 1995 Sep; 69(9):5228-35. PubMed ID: 7636964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.
    Maschera B; Darby G; Palú G; Wright LL; Tisdale M; Myers R; Blair ED; Furfine ES
    J Biol Chem; 1996 Dec; 271(52):33231-5. PubMed ID: 8969180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.
    Ermolieff J; Lin X; Tang J
    Biochemistry; 1997 Oct; 36(40):12364-70. PubMed ID: 9315877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.
    Vasudevachari MB; Zhang YM; Imamichi H; Imamichi T; Falloon J; Salzman NP
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2535-41. PubMed ID: 8913459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir.
    Melnick L; Yang SS; Rossi R; Zepp C; Heefner D
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3256-65. PubMed ID: 9835523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.
    Chen Z; Li Y; Schock HB; Hall D; Chen E; Kuo LC
    J Biol Chem; 1995 Sep; 270(37):21433-6. PubMed ID: 7665551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs.
    Nillroth U; Vrang L; Markgren PO; Hultén J; Hallberg A; Danielson UH
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2383-8. PubMed ID: 9371337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
    Patick AK; Rose R; Greytok J; Bechtold CM; Hermsmeier MA; Chen PT; Barrish JC; Zahler R; Colonno RJ; Lin PF
    J Virol; 1995 Apr; 69(4):2148-52. PubMed ID: 7884862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.
    Jacobsen H; Yasargil K; Winslow DL; Craig JC; Kröhn A; Duncan IB; Mous J
    Virology; 1995 Jan; 206(1):527-34. PubMed ID: 7831807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.
    Canducci F; Ceresola ER; Saita D; Al-Abed Y; Garotta G; Clementi M; Nicoletti F
    Antiviral Res; 2011 Sep; 91(3):292-5. PubMed ID: 21763726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease.
    Mahalingam B; Louis JM; Reed CC; Adomat JM; Krouse J; Wang YF; Harrison RW; Weber IT
    Eur J Biochem; 1999 Jul; 263(1):238-45. PubMed ID: 10429209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.
    Saen-oon S; Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Nov; 26(4):720-7. PubMed ID: 17543558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance profiles of cyclic and linear inhibitors of HIV-1 protease.
    Ahlsén G; Hultén J; Shuman CF; Poliakov A; Lindgren MT; Alterman M; Samuelsson B; Hallberg A; Danielson UH
    Antivir Chem Chemother; 2002 Jan; 13(1):27-37. PubMed ID: 12180647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A.
    Smidt ML; Potts KE; Tucker SP; Blystone L; Stiebel TR; Stallings WC; McDonald JJ; Pillay D; Richman DD; Bryant ML
    Antimicrob Agents Chemother; 1997 Mar; 41(3):515-22. PubMed ID: 9055985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
    Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
    J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome.
    Wakefield JK; Jablonski SA; Morrow CD
    J Virol; 1992 Nov; 66(11):6806-12. PubMed ID: 1383571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
    Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
    J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.